US EditionPublished • loading... • Updated
FDA unveils drugs to receive expedited review in support of ‘national priorities’
The FDA aims to cut drug review times to one or two months for nine medicines addressing major health issues, supporting U.S. national interests and lowering costs.
- On Thursday, the Food and Drug Administration announced the first round of experimental drugs to receive drastically expedited reviews as part of Trump administration priorities.
- Under the program announced earlier this year, the Food and Drug Administration aims to decide approvals in one to two months, faster than standard 10-month or six-month accelerated reviews.
- Selected items also include Pergoveris, a drug for IVF treatments, with no mention of vaping addiction, deafness, or pancreatic cancer, as reported.
- At the White House, President Donald Trump highlighted the expedited review of experimental drugs supporting U.S. national interests, with approvals expected in one to two months.
- Agency officials point to precedent, with FDA Commissioner Dr. Marty Makary suggesting the agency could speed approvals by citing the truncated COVID-19 vaccine process under Operation Warp Speed.
Insights by Ground AI
69 Articles
69 Articles
FDA Unveils Drugs to Receive Expedited Review in Support of 'National Priorities'
The Food and Drug Administration on Thursday announced the first round of experimental drugs that will receive drastically expedited reviews at the agency, part of an effort to prioritize medicines the Trump administration deems...
·Washington, United States
Read Full Article
·Washington, United States
Read Full Article
The U.S. Food and Drug Administration (FDA) announced on Thursday (October 16) that nine products will be eligible for its newly established expedited review process, with the potential for approval within one to two months after submitting a complete application.
Coverage Details
Total News Sources69
Leaning Left11Leaning Right6Center41Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
L 19%
C 71%
Factuality
To view factuality data please Upgrade to Premium
